Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
mRNA-1010 demonstrated superior relative vaccine efficacy
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
The CDMO upgrade represents a transformational step for Remedium Lifecare
Subscribe To Our Newsletter & Stay Updated